Lumosa Therapeutics Co. Ltd.
Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan, Asia, the Americas, and Europe. The company offers Naldebain (LT " 1001), an analgesic injection for severe pain relief after surgery. It is developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; L… Read more
Lumosa Therapeutics Co. Ltd. (6535) - Net Assets
Latest net assets as of December 2025: NT$1.52 Billion TWD
Based on the latest financial reports, Lumosa Therapeutics Co. Ltd. (6535) has net assets worth NT$1.52 Billion TWD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.65 Billion) and total liabilities (NT$131.04 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.52 Billion |
| % of Total Assets | 92.06% |
| Annual Growth Rate | 6.42% |
| 5-Year Change | -28.29% |
| 10-Year Change | N/A |
| Growth Volatility | 30.11 |
Lumosa Therapeutics Co. Ltd. - Net Assets Trend (2019–2025)
This chart illustrates how Lumosa Therapeutics Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Lumosa Therapeutics Co. Ltd. (2019–2025)
The table below shows the annual net assets of Lumosa Therapeutics Co. Ltd. from 2019 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$1.52 Billion | -21.18% |
| 2024-12-31 | NT$1.93 Billion | +34.92% |
| 2023-12-31 | NT$1.43 Billion | -14.45% |
| 2022-12-31 | NT$1.67 Billion | -21.18% |
| 2021-12-31 | NT$2.12 Billion | +33.86% |
| 2020-12-31 | NT$1.58 Billion | +51.33% |
| 2019-12-31 | NT$1.05 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lumosa Therapeutics Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 19427800000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$1.85 Billion | 122.56% |
| Total Equity | NT$1.51 Billion | 100.00% |
Lumosa Therapeutics Co. Ltd. Competitors by Market Cap
The table below lists competitors of Lumosa Therapeutics Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SSAW Hotels & Resorts Group Co.Ltd.
SHE:301073
|
$403.13 Million |
|
Doman Building Materials Group Ltd
PINK:CWXZF
|
$403.14 Million |
|
Henan Jindan Lactic Acid Technology
SHE:300829
|
$403.15 Million |
|
KOMORI CORP.
F:KOI
|
$403.15 Million |
|
Vontron Technology Co Ltd
SHE:000920
|
$402.70 Million |
|
Xinyaqiang Silicon Chemistry Co Ltd
SHG:603155
|
$402.70 Million |
|
Elec-Tech International Co Ltd
SHE:002005
|
$402.60 Million |
|
Inner Mongolia North Hauler Joint Stock Co Ltd
SHG:600262
|
$402.30 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lumosa Therapeutics Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,911,669,000 to 1,509,437,000, a change of -402,232,000 (-21.0%).
- Net loss of 340,540,000 reduced equity.
- Share repurchases of 56,802,000 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-340.54 Million | -22.56% |
| Share Repurchases | NT$56.80 Million | -3.76% |
| Other Changes | NT$-4.89 Million | -0.32% |
| Total Change | NT$- | -21.04% |
Book Value vs Market Value Analysis
This analysis compares Lumosa Therapeutics Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 16.85x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 17.00x to 16.85x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$8.88 | NT$151.00 | x |
| 2020-12-31 | NT$13.10 | NT$151.00 | x |
| 2021-12-31 | NT$14.04 | NT$151.00 | x |
| 2022-12-31 | NT$10.04 | NT$151.00 | x |
| 2023-12-31 | NT$8.62 | NT$151.00 | x |
| 2024-12-31 | NT$11.32 | NT$151.00 | x |
| 2025-12-31 | NT$8.96 | NT$151.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lumosa Therapeutics Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -22.56%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -950.41%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.09x
- Recent ROE (-22.56%) is below the historical average (-18.72%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -23.04% | -140.04% | 0.13x | 1.27x | NT$-345.53 Million |
| 2020 | -20.38% | -1489.83% | 0.01x | 1.13x | NT$-480.83 Million |
| 2021 | 4.53% | 552.62% | 0.01x | 1.11x | NT$-115.91 Million |
| 2022 | -30.35% | -1856.70% | 0.01x | 1.16x | NT$-657.64 Million |
| 2023 | -16.99% | -418.23% | 0.03x | 1.18x | NT$-378.11 Million |
| 2024 | -22.22% | -1084.91% | 0.02x | 1.12x | NT$-615.95 Million |
| 2025 | -22.56% | -950.41% | 0.02x | 1.09x | NT$-491.48 Million |
Industry Comparison
This section compares Lumosa Therapeutics Co. Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lumosa Therapeutics Co. Ltd. (6535) | NT$1.52 Billion | -23.04% | 0.09x | $402.75 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |